Renvela FDA Approval History
FDA Approved: Yes (First approved October 19, 2007)
Brand name: Renvela
Generic name: sevelamer carbonate
Dosage form: Tablets
Company: Genzyme Corporation
Treatment for: Hyperphosphatemia of Renal Failure
Renvela (sevelamer carbonate) is a calcium-free, metal-free, non-absorbed phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.
Development timeline for Renvela
| Date | Article |
|---|---|
| Oct 22, 2007 | Approval FDA Approves Genzyme's Renvela for Dialysis Patients |
| Dec 21, 2006 | Genzyme Files for Approval of Sevelamer Carbonate for Patients on Dialysis |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.